MARKET

LYEL

LYEL

Lyell Immunopharma, Inc.
NASDAQ
19.26
-0.41
-2.08%
Opening 15:07 03/30 EDT
OPEN
19.48
PREV CLOSE
19.67
HIGH
20.16
LOW
19.26
VOLUME
20.89K
TURNOVER
--
52 WEEK HIGH
45.00
52 WEEK LOW
7.65
MARKET CAP
448.90M
P/E (TTM)
-1.1995
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LYEL last week (0323-0327)?
Weekly Report · 17h ago
Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet
Seeking Alpha · 03/23 20:37
Lyell Immunopharma: Differentiated Dual‑Target CAR‑T Pipeline and Upcoming Clinical Milestones Support Buy Rating and Acquisition Potential
TipRanks · 03/23 10:25
Weekly Report: what happened at LYEL last week (0316-0320)?
Weekly Report · 03/23 09:24
Lyell Immunopharma CFO and Chief Business Officer Smital Shah files Form 3 initial beneficial ownership statement
Reuters · 03/16 23:25
Weekly Report: what happened at LYEL last week (0309-0313)?
Weekly Report · 03/16 09:24
Lyell Immunopharma price target raised to $39 from $32 at Lucid Capital
TipRanks · 03/13 10:40
Lyell Immunopharma misses Q4 revenue estimates
Reuters · 03/12 21:12
More
About LYEL
Lyell Immunopharma, Inc. is a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The Company has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Webull offers Lyell Immunopharma Inc stock information, including NASDAQ: LYEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LYEL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LYEL stock methods without spending real money on the virtual paper trading platform.